3-Fluoroethylamphetamine (3-FEA) is a fluorinated analog of ethylamphetamine in which a fluorine atom is placed at the 3-position of the phenyl ring. As the N-ethyl homolog of 3-FA, it belongs to both the Stimulants and Entactogen psychoactive classes, reflecting a dual pharmacological character that combines stimulant activity with meaningful serotonergic (empathogenic) properties. This makes 3-FEA more closely related in character to compounds like 3-FMA and 4-FA than to purely dopaminergic stimulants like 2-FMA.
Community experience reports describe 3-FEA as producing a distinctive blend of stimulation and empathogenic warmth — more overtly MDMA-adjacent than 3-FA but less intensely so than 4-FA. A documented experience report (posted at 27mg oral dose) describes onset at approximately 2 hours, with effects characterized by emotional openness and mild visual brightness alongside stimulant characteristics. Reddit threads compare 3-FEA to 4-FA and note that its effects are described as "neat" and generally positive at appropriate doses.
The N-ethyl substitution (compared to N-methyl in methamphetamine analogs or the N-unsubstituted amphetamine) can affect CNS penetrance and metabolite profiles — a consideration relevant to both effect duration and potential toxicity. As with all research chemical entactogens, serotonergic neurotoxicity risk with heavy use, drug interaction hazards, and the need for infrequent use are primary safety considerations.
Safety at a Glance
High Risk- Caution with Slow Onset
- Do Not Combine with 6-APB or Other Entactogens
- Toxicity: Overview As a presumed triple releasing agent with significant serotonergic activity, 3-FEA carries the dual toxicity...
- Dangerous with: Atropa belladonna, Datura, Diphenhydramine, Harmala alkaloid, 25x-NBOMe, 2C-T-x, DOx (+2 more)
- Overdose risk: Stimulant overdose from 3-FEA is a medical emergency primarily involving cardiovascular and neuro...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
insufflated
Duration
oral
Total: 4 hrs – 6 hrsinsufflated
Total: 1 hrs – 2 hrsHow It Feels
The onset of 3-FEA unfolds within thirty to forty-five minutes as a warm tide of emotional expansion. The first signs are physical: a gentle acceleration of the heart, a spreading warmth in the chest and face, and a softening of muscular tension. But the defining quality arrives shortly after, an unmistakable shift in emotional register. The world begins to feel kinder, more approachable, and populated by people who seem genuinely worth knowing.
As the experience develops, the serotonergic character of 3-FEA becomes the dominant force. Empathy deepens considerably. Conversations take on a confessional, heart-to-heart quality, and the usual barriers between inner feeling and outward expression thin dramatically. Touch becomes remarkably pleasurable, not in a sexual way necessarily, but in a way that makes simple human contact feel nourishing and significant. Music gains emotional weight, and certain melodies or harmonies can provoke waves of feeling that wash through the body like physical sensation. The stimulant component is present but secondary, providing enough energy to stay engaged and alert without overpowering the softer, warmer qualities.
At the peak, roughly ninety minutes to two hours in, 3-FEA occupies territory that overlaps with MDMA but has its own distinct texture. The empathogenic warmth is genuine and sometimes profound, but it lacks the overwhelming, almost forceful quality of MDMA's serotonin release. Instead, the emotional openness feels more voluntary, more exploratory. The body is warm, the jaw is tight, the pupils are dilated, and there may be mild nausea. Physical energy is moderate, enough for dancing but not demanding it. The overall character is intimate, reflective, and affectionate.
The offset begins around three to four hours in and is the phase where 3-FEA demands its repayment. The empathogenic glow fades with a noticeable sense of loss, and a residual flatness or melancholy may settle in as the serotonergic stimulation recedes. The body feels tired and slightly hollowed out. Appetite remains low, though thirst may be pronounced. Sleep is achievable but may be shallow. The following day often carries a subdued quality, an emotional quietness that reflects the serotonin expenditure. Full recovery typically takes one to two days.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(20)
- Abnormal heartbeat— Abnormal heartbeat (arrhythmia) is any deviation from the heart's normal rhythm — including beats th...
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Diarrhea— Diarrhea is the occurrence of frequent, loose, or watery bowel movements as a side effect of certain...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Perception of bodily heaviness— Perception of bodily heaviness is the subjective feeling that one's body has become dramatically hea...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Cognitive(18)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Ego inflation— Grandiose overconfidence and inflated self-importance, opposite of ego death, commonly produced by s...
- Emotional blunting— Reduced capacity to experience the full range of emotions, resulting in flattened affect, commonly a...
- Empathy enhancement— A state of intensified compassion and emotional openness in which one feels deeply connected to othe...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Irritability— Irritability is a sustained state of emotional reactivity in which the threshold for annoyance, frus...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
3-FEA is believed to act as a triple reuptake inhibitor and/or releasing agent at dopamine, norepinephrine, and serotonin transporters. The significant serotonergic activity suggested by its dual Stimulant/Entactogen classification and community effect reports differentiates it from 3-FA and 2-FMA, which have minimal serotonergic character.
The N-ethyl group on the amphetamine backbone modulates potency, duration, and CNS penetrance differently than N-methyl (methamphetamine) or N-H (amphetamine) substitutions. N-ethyl groups tend to reduce or modulate affinity at monoamine transporters relative to N-methyl, which may partially explain differences in the entactogenic profile compared to N-methylated analogs.
Receptor Profile
- SERT — Meaningful serotonin releasing/inhibitory activity; produces empathogenic component
- DAT — Dopamine activity drives stimulation and euphoria
- NET — Norepinephrine activity contributes to wakefulness and cardiovascular effects
Pharmacokinetics
Based on community experience reports:
- Onset: 60–120 minutes orally (notably slower onset documented in experience reports)
- Peak: 2–4 hours
- Duration: 5–8 hours
- The 27mg experience report notes onset at approximately T+2:00, consistent with the compound's reportedly gradual onset
Comparison Within the Class
3-FEA sits between 3-FA (weaker serotonergic component, more purely stimulant) and 4-FA (stronger, more MDMA-like entactogenic effects). The meta fluorine position produces less pronounced entactogenic effects than the para position (4-FA), but the N-ethyl substitution appears to moderate overall intensity compared to N-methyl analogs.
Detection Methods
Standard Drug Panel Inclusion
3-FEA (3-Fluoroethamphetamine) is a fluorinated amphetamine analogue that is generally not detected on standard 5-panel, 10-panel, or 12-panel immunoassay drug screens. The fluorine substitution on the phenyl ring alters the molecular structure sufficiently that most amphetamine-targeted antibodies in commercial immunoassays fail to recognize it. However, cross-reactivity varies between manufacturers and assay generations, so a false positive on the amphetamine channel cannot be entirely ruled out.
Urine Detection
Due to the structural similarity to amphetamine, 3-FEA (3-Fluoroethamphetamine) and its metabolites may persist in urine for approximately 2 to 4 days after a single dose. Chronic or heavy use can extend this window. The primary metabolites include deaminated and hydroxylated derivatives, though comprehensive metabolic profiling of 3-FEA (3-Fluoroethamphetamine) in humans remains limited. Standard immunoassay urine cups will typically return a negative result for 3-FEA (3-Fluoroethamphetamine) unless the specific assay has unusually broad cross-reactivity.
Blood and Saliva Detection
3-FEA (3-Fluoroethamphetamine) can be detected in blood and oral fluid for approximately 12 to 48 hours after ingestion. Blood testing is uncommon outside of clinical or forensic contexts. Oral fluid testing follows a similar window but is used primarily in roadside or workplace settings where immediate-use detection is the goal.
Hair Follicle Detection
Hair follicle analysis can theoretically detect 3-FEA (3-Fluoroethamphetamine) for up to 90 days. However, most commercial hair testing laboratories do not include fluorinated amphetamines in their standard panels. Detection requires specific method development using LC-MS/MS with reference standards for 3-FEA (3-Fluoroethamphetamine).
Confirmatory Testing
Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the definitive methods for confirming the presence of 3-FEA (3-Fluoroethamphetamine). These techniques can distinguish 3-FEA (3-Fluoroethamphetamine) from amphetamine, methamphetamine, and other substituted amphetamines with high specificity. Reference standards for 3-FEA (3-Fluoroethamphetamine) must be available to the testing laboratory for positive identification.
Reagent Testing
Marquis reagent produces no reaction or a faint orange-brown color with 3-FEA (3-Fluoroethamphetamine), which differs from the orange-to-brown response seen with standard amphetamine. Mecke reagent typically shows no reaction. Simon's reagent can help differentiate primary amines from secondary amines in the amphetamine class. Mandelin reagent may produce a faint green-brown color. These reagent responses help distinguish 3-FEA (3-Fluoroethamphetamine) from MDMA, methamphetamine, and cathinones but cannot confirm identity on their own.
Interactions
| Substance | Status | Note |
|---|---|---|
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 25x-NBOMe | Unsafe | — |
| 2C-T-x | Unsafe | — |
| DOx | Unsafe | — |
| PCP | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Caffeine | Uncertain | — |
| Cannabis | Uncertain | — |
| Cocaine | Uncertain | — |
| GBL | Uncertain | — |
History
Development and Context
3-FEA emerged as part of the systematic exploration of N-substituted fluoroamphetamine analogs. The introduction of an N-ethyl group, combined with meta-fluorine ring substitution, represented one variation in the combinatorial space of fluorinated amphetamine derivatives that appeared in the research chemical market in the 2010s.
Community Reception
Reddit community discussions describe 3-FEA as "pretty neat" — a mild endorsement that reflects its status as a compound with genuine effect but also uncertainty. The question about its comparison to 4-FA reflects ongoing community effort to understand the structure-effect relationships across the fluoroamphetamine series.
Safety Data Gaps
3-FEA represents a compound where community self-experimentation has outpaced formal research by a wide margin. The available experience data — including the 27mg trip report published in online communities — constitute the primary evidence base for understanding its effects. This underlines the need for caution.
Harm Reduction
Caution with Slow Onset
The documented 60–120 minute onset of 3-FEA is a significant redosing risk. Users who expect faster effects may add a second dose before the first has taken full effect, resulting in excess stimulation and serotonergic load. Wait at least 2–3 hours after an oral dose before evaluating whether any supplemental dose is warranted.
Do Not Combine with 6-APB or Other Entactogens
The Reddit question about combining 6-APB with 3-FEA illustrates a common temptation — but stacking serotonergic entactogens multiplies serotonergic load unpredictably and increases neurotoxicity and serotonin syndrome risk. These combinations should be avoided.
Treat as an Entactogen for Frequency Guidelines
Despite its stimulant properties, 3-FEA's serotonergic activity warrants entactogen-level caution on use frequency. Extended intervals between uses (monthly minimum; 3 months preferable) allow serotonergic recovery.
MAOI Contraindication
Absolute contraindication with all MAOIs. Risk of potentially fatal serotonin syndrome.
Dose Guidance
- Based on the documented 27mg experience report and community discussion, typical doses likely range 25–60mg orally
- Start at the low end to assess individual response to the serotonergic component
Toxicity & Safety
Overview
As a presumed triple releasing agent with significant serotonergic activity, 3-FEA carries the dual toxicity risks of both stimulants and entactogens: sympathomimetic cardiovascular effects and potential serotonergic neurotoxicity with heavy use.
Serotonergic Neurotoxicity
The serotonergic releasing activity of 3-FEA creates a theoretical risk of serotonergic neurotoxicity comparable to other serotonin-releasing amphetamines (MDMA, 4-FA). The degree of this risk in practical use conditions is unknown. Avoiding high doses and maintaining infrequent use intervals reduces this risk.
Serotonin Syndrome Risk
Combining 3-FEA with other serotonergic substances (MAOIs, SSRIs, other entactogens) creates risk of serotonin syndrome. The Reddit post asking about combining 6-APB and 3-FEA reflects real community uncertainty about these risks — such combinations should be avoided.
Cardiovascular Effects
Standard sympathomimetic cardiovascular effects apply. The slow onset documented in reports increases the risk of inadvertent overdose if users redose before initial dose has fully expressed.
Comedown
Following use, serotonin-related comedown is expected — low mood, fatigue, and emotional blunting for 1–3 days, comparable to a mild MDMA aftereffect.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Stimulant overdose from 3-FEA is a medical emergency primarily involving cardiovascular and neurological toxicity.
Signs of overdose: Extremely rapid or irregular heartbeat, chest pain, severe headache, dangerously elevated body temperature, seizures, agitation progressing to psychosis, confusion, and loss of consciousness.
Emergency response:
- Call emergency services immediately
- Keep the person cool (remove excess clothing, apply cool water)
- If seizures occur, protect the head and clear the area of hard objects
- If the person loses consciousness, place in recovery position
- Do not give the person more stimulants, caffeine, or depressants unless directed by medical professionals
Prevention: Pre-measure doses. Avoid redosing. Stay hydrated (but don't overhydrate). Take breaks from physical activity. Monitor heart rate if possible. Have someone present who can recognize warning signs.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 2 - 3 days |
| Zero | 3-7 days |
Cross-tolerances
Legal Status
3-FEA is currently a grey area compound within many parts of the world, meaning its regulation lies in a legal grey area and that it is not known to be specifically illegal ("scheduled") within any country. However, individuals may still be charged for its possession under certain circumstances such as under analog laws and with intent to sell or consume.
Austria: 3-FEA is illegal to produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Canada: 3-FEA would be considered Schedule I as it is an analog of Amphetamine.
France: As of december 2024, 3-FEA is not explicitly scheduled. It is thus legal to possess, although in a grey area.
Germany: 3-FEA is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
New Zealand: 3-FEA is an amphetamine analog, so is a Schedule 3 controlled substance in New Zealand.
Switzerland: 3-FEA can be considered a controlled substance as a defined derivative of a-methylphenethylamine under Verzeichnis E point 130. It is legal when used for scientific or industrial use.
The Netherlands:** 3-FEA is a controlled substance as of July 1, 2025.
United Kingdom: 3-FEA is considered a Class A drug as a result of the amphetamine analog clause of the Misuse of Drugs Act 1971.
United States: 3-FEA may be considered to be an analogue of amphetamine under the Federal Analogue Act and thus a Schedule II drug. The Federal Analogue Act, 21 U.S.C. § 813, is a section of the United States Controlled Substances Act, allowing any chemical "substantially similar" to an illegal drug (in Schedule I or II) to be treated as if it were also in Schedule I or II, but only if it is intended for human consumption.
Responsible use
Designer drug
Stimulants
Substituted amphetamines
3-FEA (Wikipedia)
3-FEA (Isomer Design)
Experience Reports (4)
Tips (10)
Do not combine 3-FEA with other serotonergic substances like 6-APB, MDMA, or MAOIs. Taking 6-APB while still on 3-FEA risks serotonin syndrome. Wait at least 24 hours between serotonergic substances.
Test 3-FEA with appropriate reagent kits and fentanyl test strips. Stimulant supplies have increasingly been found contaminated with fentanyl, which has caused a surge in overdose deaths among stimulant users.
Weigh your dose of 3-FEA with a milligram scale. Street stimulants vary wildly in purity and potency. What looks like a normal amount could be significantly stronger than expected, especially with a new batch.
3-FEA causes noticeable sweating, jaw tension, and appetite suppression similar to MDMA. Magnesium supplements can help with bruxism. The day-after recovery is much milder than MDMA — most users report feeling only slightly drained.
3-FEA provides a relaxing, empathogenic roll rather than an intense stimulant push. Many users describe it as body-heavy with strong tactile euphoria and enhanced sociability, more like a gentle MDMA than a stimulant.
60-80mg oral is a good starting dose. Onset is 60-90 minutes, peak effects last about 2-3 hours. Redosing with 30mg insufflated can extend the experience but increases jaw tension significantly.
Community Discussions (8)
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- MDMA-assisted therapy for PTSD — Mithoefer et al. Psychopharmacology (2019)paper
- 3-FEA - TripSit Factsheet
TripSit factsheet for 3-FEA
tripsit - 3-FEA - Wikipedia
Wikipedia article on 3-FEA
wikipedia